Heat Biologics, Inc. to Present at the 17th Annual Global Investment Conference
DURHAM, N.C., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NASDAQ:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that Jeff Wolf, CEO, will present a corporate update at the Rodman and Renshaw 17th Annual Global Investment Conference in New York City on September 9 at 11:40 a.m. Eastern Time.
| Rodman & Renshaw 17th Annual Global Investment Conference | |
| Date: | Wednesday, September 9 |
| Time: | 11:40 a.m. Eastern Time |
| Location: | St. Regis Hotel, Library Room |
| Webcast: | http://ir.heatbio.com/events-presentations |
Links to a live audio webcast and replay of the presentation may be accessed on Heat Biologics' website at http://ir.heatbio.com/events-presentations.
About Heat Biologics, Inc.
Heat Biologics, Inc. (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" ImPACT and ComPACT therapeutic vaccines to combat a wide range of cancers. Our therapies are designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens, together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat is conducting a Phase 2 trial with its vesigenurtacel-L (HS-410) in patients with non-muscle invasive bladder cancer, as well as a Phase 1b trial of its viagenpumatucel-L (HS-110) in patients with non-small cell lung cancer.
CONTACT: Heat Biologics, Inc.
Jennifer Almond
Investor Relations
919-240-7133
investorrelations@heatbio.com
Released September 2, 2015